Di(2-ethylhexyl) phthalate (DEHP) is a common plasticizer that can affect immune system development and susceptibility to infection. Aging processes (measured as epigenetic age acceleration (EAA)) may mediate the immune-related effects of prenatal exposure to DEHP. This study’s objective was to examine associations between prenatal DEHP exposure, EAA at three months of age, and the number of upper respiratory infections (URIs) from 12 to 18 months of age using a sample of 69 maternal–child pairs from a Canadian pregnancy cohort. Blood DNA methylation data were generated using the Infinium HumanMethylation450 BeadChip; EAA was estimated using Horvath’s pan-tissue clock. Robust regressions examined overall and sex-specific associations. Higher prenatal DEHP exposure (B = 6.52, 95% CI = 1.22, 11.81) and increased EAA (B = 2.98, 95% CI = 1.64, 4.32) independently predicted more URIs. In sex-specific analyses, some similar effects were noted for boys, and EAA mediated the association between prenatal DEHP exposure and URIs. In girls, higher prenatal DEHP exposure was associated with decreased EAA, and no mediation was noted. Higher prenatal DEHP exposure may be associated with increased susceptibility to early childhood URIs, particularly in boys, and aging biomarkers such as EAA may be a biological mechanism. Larger cohort studies examining the potential developmental immunotoxicity of phthalates are needed.
Glycosylation is the most common form of post-translational modification of proteins, critically affecting their structure and function. Using liquid chromatography and mass spectrometry for high-resolution site-specific quantification of glycopeptides coupled with high-throughput artificial intelligence-powered data processing, we analyzed differential protein glycoisoform distributions of 597 abundant serum glycopeptides and nonglycosylated peptides in 50 individuals who had been seriously ill with COVID-19 and in 22 individuals who had recovered after an asymptomatic course of COVID-19. As additional comparison reference phenotypes, we included 12 individuals with a history of infection with a common cold coronavirus, 16 patients with bacterial sepsis, and 15 healthy subjects without history of coronavirus exposure. We found statistically significant differences, at FDR < 0.05, for normalized abundances of 374 of the 597 peptides and glycopeptides interrogated between symptomatic and asymptomatic COVID-19 patients. Similar statistically significant differences were seen when comparing symptomatic COVID-19 patients to healthy controls (350 differentially abundant peptides and glycopeptides) and common cold coronavirus seropositive subjects (353 differentially abundant peptides and glycopeptides). Among healthy controls and sepsis patients, 326 peptides and glycopeptides were found to be differentially abundant, of which 277 overlapped with biomarkers that showed differential expression between symptomatic COVID-19 cases and healthy controls. Among symptomatic COVID-19 cases and sepsis patients, 101 glycopeptide and peptide biomarkers were found to be statistically significantly abundant. Using both supervised and unsupervised machine learning techniques, we found specific glycoprotein profiles to be strongly predictive of symptomatic COVID-19 infection. LASSO-regularized multivariable logistic regression and K-means clustering yielded accuracies of 100% in an independent test set and of 96% overall, respectively. Our findings are consistent with the interpretation that a majority of glycoprotein modifications observed which are shared among symptomatic COVID-19 and sepsis patients likely represent a generic consequence of a severe systemic immune and inflammatory state. However, there are glycoisoform changes that are specific and particular to severe COVID-19 infection. These may be representative of either COVID-19-specific consequences or susceptibility to or predisposition for a severe course of the disease. Our findings support the potential value of glycoproteomic biomarkers in the biomedical understanding and, potentially, the clinical management of serious acute infectious conditions.
Age- and sex-related differences in immune cell compositions and immune outcomes have been identified across the life course, but a comprehensive and nuanced characterization of these changes during the rapid developmental window of early life is lacking. We explore immune associated DNA methylation (DNAm) changes in the context of age and sex leveraging whole blood samples collected at ages one and five from CHILD, a Canadian longitudinal pediatric cohort (n = 760: 356 female and 404 male). DNAm-based computational cell type deconvolution reveals significant changes in all estimated immune cell types across time, with notable sex differences. In addition, we identify distinct DNAm signatures reflecting age- and sex-associated immune profiles in early life. While age-related DNAm changes are relatively limited, sex-associated differences are consistent across this developmental window and partially validate in independent pediatric cohorts. Together, these findings provide insights into early immune system maturation, underscoring the presence of sex differences prior to puberty.
Genetic variation and environmental exposures are amongst the main factors associated with inter-individual DNA methylation variability. However, the prevalence and genomic context of individual, additive, and interactive gene-environment effects remains unclear. We present RAMEN, an R package that dissects genome-exposome contributions to microarray Variably Methylated Loci using machine learning and statistical techniques. Analyzing cord blood samples from CHILD and PREDO (overall n = 1662), we identify genetic variants as key contributors to DNA methylation variability, usually in additive and interactive combinations with the environment. We provide a detailed catalogue of cord blood Variably Methylated Loci and the gene-environment contribution to their variability.
Background The vast majority of SARS-CoV-2 infections are uncomplicated and do not require hospitalization, but contribute to ongoing transmission. Our understanding of the clinical course of uncomplicated COVID-19 remains limited. Methods We detailed the natural history of uncomplicated COVID-19 among 120 outpatients enrolled in a randomized clinical trial of Peginterferon Lambda. We characterized symptom trajectory and clusters using exploratory factor analysis, assessed predictors of symptom resolution and cessation of oropharyngeal viral shedding using Cox proportional hazard models, and evaluated associations between symptoms and viral shedding using mixed effects linear models. Results Headache, myalgias and chills peaked at day 4 after symptom onset; cough peaked on day 9. Two distinct symptom cluster trajectories were identified; one with mild, upper respiratory symptoms, and the other with more severe and prolonged inflammatory symptoms. The median time to symptom resolution from earliest symptom onset was 17 days (95% CI 14-18). Neither enrollment SARS-CoV-2 IgG levels (Hazard ratio [HR] 1.88, 95% CI 0.84-4.20) nor oropharyngeal viral load at enrollment (HR 1.01, 95% CI 0.98-1.05) were significantly associated with the time to symptom resolution. The median time to cessation of viral shedding was 10 days (95% CI 8-12), with higher SARS-CoV-2 IgG levels at enrollment associated with hastened resolution of viral shedding (HR 3.12, 95% CI 1.4-6.9, p=0.005). Myalgia, joint pains, and chills were associated with a significantly greater odds of oropharyngeal SARS-CoV-2 RNA detection. Conclusions In this outpatient cohort, inflammatory symptoms peaked early and were associated with ongoing SARS-CoV-2 replication. SARS-CoV-2 antibody levels were associated with more rapid viral shedding cessation, but not with time to symptom resolution. These findings have important implications for COVID-19 screening approaches and clinical trial design.
Prospective birth cohorts offer the potential to interrogate the relation between early life environment and embedded biological processes such as DNA methylation (DNAme). These association studies are frequently conducted in the context of blood, a heterogeneous tissue composed of diverse cell types. Accounting for this cellular heterogeneity across samples is essential, as it is a main contributor to inter-individual DNAme variation. Integrated blood cell deconvolution of pediatric and longitudinal birth cohorts poses a major challenge, as existing methods fail to account for the distinct cell population shift between birth and adolescence. In this paper, we critically evaluated the reference-based deconvolution procedure and optimized its prediction accuracy for longitudinal birth cohorts using DNAme data from the Canadian Healthy Infant Longitudinal Development (CHILD) cohort. The optimized algorithm, CellsPickMe , integrates cord and adult references and picks DNA me features for each population of cells with machine learning algorithms. It demonstrated improved deconvolution accuracy in cord, pediatric, and adult blood samples compared to existing benchmark methods. CellsPickMe supports blood cell deconvolution across early developmental periods under a single framework, enabling cross-time-point integration of longitudinal DNAme studies. Given the increased resolution of cell populations predicted by CellsPickMe , this R package empowers researchers to explore immune system dynamics using DNAme data in population studies across the life course.